June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
OC-01 (varenicline solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2
Author Affiliations & Notes
  • Anat Galor
    Surgical Services, VA Miami Healthcare System, Miami, Florida, United States
    University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Andrea Gibson
    Oyster Point Pharma, Princeton, New Jersey, United States
  • Gretchen Blemker
    Oyster Point Pharma, Princeton, New Jersey, United States
  • Laura Hendrix
    Oyster Point Pharma, Princeton, New Jersey, United States
  • Footnotes
    Commercial Relationships   Anat Galor Novaliq, Code C (Consultant/Contractor), Dompe, Code C (Consultant/Contractor), Astrazenica, Code C (Consultant/Contractor), Oyster Point, Code C (Consultant/Contractor), Tarsus, Code C (Consultant/Contractor), Oculis, Code C (Consultant/Contractor), Novartis, Code C (Consultant/Contractor); Andrea Gibson Oyster Point Pharma, Code E (Employment); Gretchen Blemker Oyster Point Pharma, Code E (Employment); Laura Hendrix Oyster Point Pharma, Code E (Employment)
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1506 – A0231. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anat Galor, Andrea Gibson, Gretchen Blemker, Laura Hendrix; OC-01 (varenicline solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1506 – A0231.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Among patients with dry eye disease (DED), those with systemic autoimmune disease (AID) experience signs and symptoms often more serious with worse treatment effect and prognoses. This analysis evaluated the outcome of DED subjects with documented AID treated with OC-01 (varenicline solution) nasal spray (OC-01 VNS), a cholinergic agonist, compared to vehicle control (VC). OC-01 VNS has been shown to activate the trigeminal parasympathetic pathway to produce basal tear film by stimulating the lacrimal functional unit.

Methods : In ONSET-1, 182 patients were randomized 1:1:1:1 to receive 0.006 mg, 0.03 mg, or 0.06 mg OC-01 VNS or VC. In ONSET-2, 758 patients were randomized 1:1:1 to receive 0.03 mg or 0.06 mg OC-01 VNS or VC. Subjects administered OC-01 VNS or VC once to each nostril twice daily for 4 weeks. For this sub-population of interest, a total of 31 AID subjects were analyzed based on OC-01 VNS treated (0.03 mg or 0.06 mg, n=20) and VC (n=11) groups. Respectively, OC-01 VNS treated and VC mean baseline (BL) values were Schirmer’s Test Score (STS, mm): 5.6 and 4.2; Eye Dryness Score (EDS, 0-100): 59.2 and 52.7. Outcome measures from BL to Week 4 included STS and mean change in EDS. Differences in OC-01 VNS treated and VC subjects were compared using t-test and chi square tests.

Results : OC-01 VNS treated subjects showed directional benefit in STS and EDS outcomes compared to VC. For OC-01 VNS treated and VC groups from BL to Week 4, respectively, percentage of eyes demonstrating improvement in STS ≥10 mm: 61.1% and 0.0% (95% CI, 46.0-76.2%); mean change in STS: 13.6mm and 1.8mm (6.5-17.1); and mean change in EDS: -19.6 and -10.3 (-26.8-8.2). OC-01 VNS was well tolerated in the trials. Most common adverse reaction in OC-01 VNS treated groups was sneeze (82-84%); the majority (98%) reported it as mild. Other adverse reactions >5% included cough, throat, and instillation site (nose) irritation.

Conclusions : In a sub-population with potential to have worse DED, OC-01 VNS treated AID subjects demonstrated directional signaled benefits in DED signs and symptoms at Week 4 compared to VC despite a limited sample size. OC-01 VNS was shown to have a favorable safety and tolerability profile in the trials. Future prospective studies with larger AID subject sample sizes are recommended.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×